Treatment of idiopathic oligozoospermia by kallikrein: results of a double-blind study.

Abstract

Ninety subfertile men with idiopathic oligozoospermia were treated orally with either 600 units porcine pancreatic kallikrein or placebo daily for 7 wk. Kallikrein caused an increase in the number of spermatozoa (3.1 X 10(7) with a maximum 2--3 mo after onset of therapy. There was an improvement of the quantitative and qualitative sperm motility with a maximum at the end of treatment. Five months after onset of therapy, pretreatment values were regained. There were no major side effects. Conception rates within a period of 1 yr were 16% for placebo and 38% for kallikrein.

• Authors: W B Schill
• Journal: Archives of andrology (Arch Androl) Vol. 2 Issue 2 Pg. 163-70 (Mar 1979) ISSN: 0148-5016 [Print] England
• PMID: 573602 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Kallikreins

Topics

• Animals
• Double-Blind Method
• Evaluation Studies as Topic
• Female
• Humans
• Kallikreins (adverse effects, pharmacology, therapeutic use)
• Male
• Oligospermia (drug therapy)
• Pregnancy
• Sperm Motility (drug effects)
• Spermatogenesis (drug effects)
• Swine